In fact, recent data suggest that patients with EGFR-mutant lung cancer selected for high tumor MET protein expression have infrequent co-occurring MET amplification (24), whereas the majority of patients with MET FISH amplified tumors are also MET IHC positive (19), indicating that correlations among the various methodologies for detecting MET activity are not well defined. This evidence concerns the gene EGFR and lung cancer.